LDS/Medical Tests/Dihydrocodeine, Urine

Dihydrocodeine, Urine

Dihydrocodeine is a semisynthetic opioid agonist that is used as an alternate to codeine. Dihydrocodeine is often coformulated with other drugs such as aspirin or acetaminophen, paracetamol, chlorpheniramine and/or phenylephrine. The typical route of administration is oral. Dihydrocodeine is widely available without a prescription outside the US, such as in Europe and Japan. Dihydrocodeine is metabolized into a glucuronide conjugate and excreted into the urine. The half-life of dihydrocodeine is 3.4-4.5 hours. The duration of analgesia is 3-4 hours.

Approximately 90 percent of a single dose appears in the urine within 24 hours. Actual elimination depends on factors such as drug formulation, dose, dose frequency, clinical status and pharmacokinetics of the individual patient.

Common side effects: respiratory depression, sedation, nausea, vomiting, dizziness, miosis, constipation, urinary retention. Dihydrocodeine can also contribute to the following effects: euphoria, mental clouding, amnesia, hostility, irritability, pruritis, and vivid or disturbing dreams. Can be addictive. Overdose effects include respiratory collapse, seizure, coma, and possible death.

Dihydrocodeine and metabolites can be detected in urine by a variety of analytical methods (see below); both qualitative and quantitative tests are available.

  • Adherence monitoring
  • Drug abuse evaluation
  • Toxicity/Overdose assessment
A positive result indicates the presence of Dihydrocodeine and does not necessarily correlate with the extent of physiological and psychological effects. Note that dihydrocodeine is equivalent to the common hydrocodone metabolite, hydrocodol. As such, a dihydrocodeine result may reflect use of hydrocodone rather than dihydrocodeine. Any result that is inconsistent with clinical expectations should be confirmed or quantitated by a second method.

Therapeutic Level: 10-100 ng/ml
Toxic level: >200 ng/ml

Note: therapeutic ranges and toxic thresholds are best evaluated from blood samples. Quantitative results obtained with blood samples collected at specific times after drug administration are preferred for pharmacokinetic analyses.

Cut-Off Ranges

Cut-off values are used to determine the positivity of the urine specimen being analyzed. Cut-off values can vary based on the particular method of analysis that is used for detection, or laboratory, or whether the test is a qualitative method or a quantitative method. The testing laboratory cut-off range is listed on the patient report.

Many, including Liquid Chromatography/Mass Spectroscopy (LC/MS or LC-MS/MS), Gas Chromatography/Mass Spectroscopy (GC/MS), or Thin Layer Chromatography (TLC). A pre-analytical hydrolysis reaction to liberate the glucuronide conjugates may improve detection. Commercial immunoassays specific to dihydrocodeine are not available.

Urine

Fresh urine specimen (random) collected in either a clean glass or plastic container. An acceptable urine specimen submitted for testing should be in the pH range of 3-11. Creatinine or specific gravity results will identify dilute specimens. Adulteration of the urine specimen can result in erroneous results.

Stability

  • Ambient: 5 days
  • Refrigeration: 7 days
  • Frozen: 30 days
Pharmacogenetic testing such as genotyping for *CYP3A4, CYP3A5, CYP2D6, CYP2C9, CYP2C19, and OPRM1* variants could guide drug and dose selection. Supportive testing such as liver profile, kidney profile, comprehensive metabolic panel, CBC (if overdose), and testing for concomitant drugs may be appropriate.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Baselt RC (ed). Disposition of toxic drugs and chemicals in man, 9th ed. Forster City, CA: Biomedical Publications; 2011.
  • Brunton LL, Chabner B, Knollman B (eds). Goodman and Gilmans the pharmacological basis of therapeutics, 12th ed. New York: McGraw-Hill; 2010.
  • Katzung BG, Masters S, Trevor AK (eds). Basic and clinical pharmacology, 12th ed. New York: McGraw-Hill; 2011.